M. Ainsworth

Most-cited papers

1. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

   Obbina Ali Fatima Mustafa Sadia Hakam Alfie Nabeel Ashraf Abani Abbas Abbas Abbas Abbasi Abbass Abbott Abdal, O. Abani, A. Abbas, F. Abbas +496 more

   2021The Lancet1,685 citations Open access

   Semantic Scholar

   Save

2. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

   C. Steenholdt, J. Brynskov, O. Thomsen, L. Munck +9 more

   2013Gut468 citations

   Semantic Scholar

   Save

3. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

   M. Ainsworth, M. Andersson, K. Auckland, J. Baillie +126 more

   2020Lancet. Infectious Diseases (Print)381 citations Open access

   Semantic Scholar

   Save

4. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

   Eugenia Mustafa Sadia Alfie Ashraf Sherif Mohamed Basir Al Abaleke Abbas Abbasi Abbott Abdelaziz Abdelbadiee , E. Abaleke, M. Abbas, Sadia Abbasi +496 more

   2021The Lancet289 citations Open access

   Semantic Scholar

   Save

5. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

   C. Steenholdt, K. Bendtzen, J. Brynskov, O. Thomsen +1 more

   2011Scandinavian Journal of Gastroenterology187 citations

   Semantic Scholar

   Save

6. Tumor necrosis factor inhibitors for inflammatory bowel disease.

   O. H. Nielsen, M. Ainsworth

   2013New England Journal of Medicine180 citations

   Semantic Scholar

   Save

7. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

   C. Steenholdt, M. Svenson, K. Bendtzen, O. O. Thomsen +2 more

   2011Alimentary Pharmacology and Therapeutics158 citations Open access

   Semantic Scholar

   Save

8. Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial

   C. Steenholdt, K. Bendtzen, J. Brynskov, O. Thomsen +1 more

   2014American Journal of Gastroenterology143 citations

   Semantic Scholar

   Save

9. Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease

   C. Steenholdt, M. Ainsworth, M. Tovey, T. Klausen +3 more

   2013Therapeutic Drug Monitoring116 citations

   Semantic Scholar

   Save

10. Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD

    Madeline T. Frederiksen, M. Ainsworth, J. Brynskov, O. Thomsen +2 more

    2014Inflammatory Bowel Diseases111 citations

    Semantic Scholar

    Save

11. Clinical implications of variations in anti‐infliximab antibody levels in patients with inflammatory bowel disease

    C. Steenholdt, M. Al-khalaf, J. Brynskov, K. Bendtzen +2 more

    2012Inflammatory Bowel Diseases110 citations

    Semantic Scholar

    Save

12. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists.

    C. Lallemand, Nadia Kavrochorianou, C. Steenholdt, K. Bendtzen +8 more

    2011JIM - Journal of Immunological Methods109 citations

    Semantic Scholar

    Save

13. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies

    C. Steenholdt, K. Bendtzen, J. Brynskov, M. Ainsworth

    2016Inflammatory Bowel Diseases99 citations

    Semantic Scholar

    Save

14. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study

    C. Steenholdt, A. Molazahi, M. Ainsworth, J. Brynskov +2 more

    2012Scandinavian Journal of Gastroenterology97 citations

    Semantic Scholar

    Save

15. Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease

    O. H. Nielsen, M. Ainsworth, M. Coşkun, G. Weiss

    2015Medicine88 citations Open access

    Semantic Scholar

    Save

16. Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn’s Disease Patients Failing Infliximab

    C. Steenholdt, J. Brynskov, O. Thomsen, L. Munck +9 more

    2015Digestive Diseases and Sciences82 citations

    Semantic Scholar

    Save

17. Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population‐based cohort study 1977‐2011

    J. Ø. Sørensen, O. H. Nielsen, M. Andersson, M. Ainsworth +3 more

    2018Liver international (Print)76 citations

    Semantic Scholar

    Save

18. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease.

    C. Steenholdt, M. Svenson, K. Bendtzen, O. Thomsen +2 more

    2012Journal of Crohn's & Colitis75 citations Open access

    Semantic Scholar

    Save

19. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.

    C. Steenholdt, K. Bendtzen, J. Brynskov, O. Thomsen +5 more

    2015Journal of Crohn's & Colitis70 citations

    Semantic Scholar

    Save

20. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health

    A. Moolla, K. Motohashi, T. Marjot, Amelia Shard +7 more

    2019Frontline Gastroenterology68 citations Open access

    Semantic Scholar

    Save

21. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease

    C. Steenholdt, C. Enevold, M. Ainsworth, J. Brynskov +2 more

    2012Alimentary Pharmacology and Therapeutics53 citations Open access

    Semantic Scholar

    Save

22. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

    J. Bjerrum, C. Steenholdt, M. Ainsworth, O. H. Nielsen +5 more

    2017BMC Medicine52 citations Open access

    Semantic Scholar

    Save

23. Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31.

    C. Steenholdt, M. Al-khalaf, M. Ainsworth, J. Brynskov

    2012Journal of Crohn's & Colitis38 citations Open access

    Semantic Scholar

    Save

24. Prevalence and severity of non‐alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital

    T. Marjot, E. Sbardella, A. Moolla, J. Hazlehurst +4 more

    2018Diabetic Medicine37 citations Open access

    Semantic Scholar

    Save

25. A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease

    D. Mogensen, J. Brynskov, M. Ainsworth, J. Nersting +2 more

    2018Journal of Crohn's & Colitis29 citations

    Semantic Scholar

    Save

26. Will novel oral formulations change the management of inflammatory bowel disease?

    O. H. Nielsen, J. Seidelin, M. Ainsworth, M. Coşkun

    2016Expert Opinion on Investigational Drugs29 citations

    Semantic Scholar

    Save

27. Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNFα Therapy

    K. Christensen, C. Steenholdt, S. Buhl, M. Ainsworth +2 more

    2015American Journal of Gastroenterology28 citations

    Semantic Scholar

    Save

28. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: A Danish single center experience

    A. Teisner, M. Ainsworth, J. Brynskov

    2010Scandinavian Journal of Gastroenterology28 citations

    Semantic Scholar

    Save

29. Discontinuation of Infliximab Therapy in Patients with Crohn's Disease.

    S. Buhl, C. Steenholdt, J. Brynskov, K. Christensen +23 more

    2022NEJM Evidence27 citations

    Semantic Scholar

    Save

30. Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn’s Disease Is Determined by Their Concentration

    H. Edlund, C. Steenholdt, M. Ainsworth, E. Goebgen +4 more

    2016AAPS Journal27 citations

    Semantic Scholar

    Save

31. Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease

    C. Steenholdt, Madeline T. Frederiksen, K. Bendtzen, M. Ainsworth +2 more

    2016Journal of Clinical Gastroenterology25 citations

    Semantic Scholar

    Save

32. Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial

    S. Buhl, C. Steenholdt, J. Brynskov, O. Thomsen +2 more

    2014BMJ Open25 citations Open access

    Semantic Scholar

    Save

33. Withdrawal of Immunomodulators or TNF Antagonists in Patients with Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis.

    David J Katibian, V. Solitano, D. B. Polk, Nguyen Tran +8 more

    2023Clinical Gastroenterology and Hepatology21 citations Open access

    Semantic Scholar

    Save

34. Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease

    S. Buhl, C. Steenholdt, M. Rasmussen, M. Borghede +3 more

    2017Inflammatory Bowel Diseases21 citations

    Semantic Scholar

    Save

35. Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease.

    C. Steenholdt, J. Brynskov, O. Thomsen, L. Munck +4 more

    2015Journal of Crohn's & Colitis21 citations Open access

    Semantic Scholar

    Save

36. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease

    S. Buhl, M. Dorn-Rasmussen, J. Brynskov, M. Ainsworth +5 more

    2020Scandinavian Journal of Gastroenterology20 citations

    Semantic Scholar

    Save

37. Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics

    K. Christensen, M. Ainsworth, C. Steenholdt, S. Buhl +4 more

    2022Scandinavian Journal of Gastroenterology17 citations Open access

    Semantic Scholar

    Save

38. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease

    Ana-Marija Grisic, M. Dorn-Rasmussen, B. Ungar, J. Brynskov +8 more

    2020United European Gastroenterology journal17 citations Open access

    Semantic Scholar

    Save

39. Telephone reminders reduced the non-attendance rate in a gastroenterology outpatient clinic.

    Maja Haunstrup Jeppesen, M. Ainsworth

    2015Danish Medical Journal15 citations

    Semantic Scholar

    Save

40. Challenges and opportunities for IBD drug development: from early stage to regulatory approval

    S. Danese, Elmer Schabel, M. Ainsworth, L. Peyrin-Biroulet

    2020Gut13 citations

    Semantic Scholar

    Save

41. Identifying and understanding disease burden in patients with inflammatory bowel disease

    K. Christensen, M. Ainsworth, M. Skougaard, C. Steenholdt +4 more

    2022BMJ Open Gastroenterology12 citations Open access

    Semantic Scholar

    Save

42. A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients’ and physicians’ preferences and adherence

    K. Christensen, C. Steenholdt, S. Buhl, J. Brynskov +1 more

    2021Scandinavian Journal of Gastroenterology12 citations Open access

    Semantic Scholar

    Save

43. Biological Treatment of Crohn’s Disease

    O. H. Nielsen, J. Bjerrum, J. Seidelin, Caroline Nyberg +1 more

    2013Digestive Diseases12 citations

    Semantic Scholar

    Save

44. Methotrexate for inflammatory bowel disease: time for reconsideration

    O. H. Nielsen, M. Ainsworth, C. Steenholdt

    2019Expert Review of Gastroenterology & Hepatology9 citations Open access

    Semantic Scholar

    Save

45. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease

    R. Holmstrøm, D. Mogensen, J. Brynskov, M. Ainsworth +3 more

    2018Digestive Diseases and Sciences9 citations

    Semantic Scholar

    Save

46. Authors’ response: Importance of defining loss of response before therapeutic drug monitoring

    C. Steenholdt, M. Ainsworth

    2015Gut8 citations

    Semantic Scholar

    Save

47. 94 Treatment of Secondary Infliximab Failure in Crohn's Disease Based on Serum Levels of Infliximab and Antibodies Against Infliximab: The Danish Study of Optimizing Infliximab Therapy in Crohn's Disease (Do It Crohn) Randomized Clinical Trial

    C. Steenholdt, J. Brynskov, O. Thomsen, L. Munck +9 more

    20137 citations Open access

    Semantic Scholar

    Save

48. Which Biological Agents Are Most Appropriate for Ulcerative Colitis?

    O. H. Nielsen, M. Ainsworth

    2014Annals of Internal Medicine6 citations

    Semantic Scholar

    Save

49. Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay: authors’ reply

    C. Steenholdt, M. Svenson, K. Bendtzen, O. O. Thomsen +2 more

    20116 citations Open access

    Semantic Scholar

    Save

50. Tu1236 Comparison of Techniques for Monitoring Infliximab Bioavailability and Immunogenicity in Crohn's Disease

    C. Steenholdt, M. Svenson, M. Ainsworth, O. Thomsen +2 more

    20125 citations

    Semantic Scholar

    Save